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Background: This study aimed to evaluate the effect of perioperative supplementation with omega-3
fatty acids (n-3 FA) on perioperative outcomes and survival in patients undergoing colorectal cancer
surgery.
Methods: Patients scheduled for elective resection of colorectal cancer between 2007 and 2010 were
randomized to either an n-3 FA-enriched oral nutrition supplement (ONS) twice daily or a standard ONS
(control) for 7 days before and after surgery. Outcome measures, including postoperative complications,
3-year cumulative incidence of local or metastatic colorectal cancer recurrence and 5-year overall survival,
were compared between the groups.
Results: Of 148 patients enrolled in the study, 125 (65 patients receiving n-3 FA-enriched ONS and 60
receiving standard ONS) were analysed. There were no differences in postoperative complications after
surgery (P = 0⋅544). The risk of disease recurrence at 3 years was similar (relative risk 1⋅66, 95 per cent c.i.
0⋅65 to 4⋅26).The 5-year survival rate of patients treated with n-3 FA was 69⋅2 (95 per cent c.i. 56⋅5 to 78⋅9)
per cent, compared with 81⋅7 (69⋅3 to 89⋅4) per cent in the control group (P = 0⋅193). After adjustment for
age, stage of disease and adjuvant chemotherapy, n-3 FA was associated with higher mortality compared
with controls (hazard ratio 1⋅73, 95 per cent c.i. 1⋅06 to 2⋅83; P = 0⋅029). The interaction between n-3
FA and adjuvant chemotherapy was not statistically significant.
Conclusion: Perioperative supplementation with n-3 FA did not confer a survival benefit in patients
undergoing colorectal cancer surgery. n-3 FA did not benefit the subgroup of patients treated with
adjuvant chemotherapy or decrease the risk of disease recurrence.
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Introduction
Colorectal cancer surgery has been associated with a phase
of hyperinflammation followed by a relative immune
incompetence1,2. Patients’ nutritional status and, in partic-
ular, the availability of specific biologically active nutrients,
such as the marine omega-3 fatty acids (n-3 FA) (eicosa-
pentaenoic acid (EPA), docosahexaenoic acid (DHA))
and docosapentaenoic acid, have been investigated in
the literature3–7 as factors influencing the postoperative
course. In particular, n-3 FA have been associated with an
improved immunoproliferative response8.
Several colorectal cancer cell line studies have investi-
gated also whether n-3 FA could improve the response
to chemotherapeutic agents. A previous study9 demon-
strated a synergistic anticancer effect between EPA and a
regimen of 5-fluorouracil (5-FU) and oxaliplatin in vitro
© 2020 The Authors. BJS Open published by John Wiley & Sons Ltd on behalf of BJS Society Ltd BJS Open 2020; 4: 678–684
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and in vivo against the human colonic cancer cells. In
line with this, other researchers10 hypothesized that EPA
could have a role in adjuvant therapy for the prevention
of metastatic colorectal cancer. Oral administration of
EPA reduced the growth of experimental colorectal cancer
liver metastases and, importantly, preoperative treatment
with EPA resulted in improved disease-free survival10.
Finally, it has been proposed11 that n-3 FA might increase
the susceptibility of tumour cells to chemotherapeutic
regimens: in an experimental study conducted on mice
with colonic cancer, the administration of 5-FU and n-3
FA increased both DNA damage and the apoptotic index
by activation of extrinsic and intrinsic apoptotic pathways.
The increased proapoptotic effect by the synergism of
5-FU and n-3 FA could be attributed to the incorpora-
tion of n-3 FA into the cancer cell membranes, altering
membrane fluidity and thereby chemosensitizing the
tumour cells.
The aim of the present study was to investigate whether
oral supplementation with n-3 FA in the perioperative
period might be associated with improved postoperative
outcomes (decreased number of complications), decreased
risk of disease recurrence, and improved survival in patients
undergoing colorectal cancer surgery.
Methods
A randomized, double-blind, placebo-controlled, single-
centre trial was conducted to study the effect of an
n-3 FA-enriched oral nutrition supplement (ONS) on
long-term outcomes in patients scheduled for colorectal
cancer surgery.
Patients scheduled for colorectal cancer surgery at the
Department of Gastrointestinal Surgery, Aalborg Uni-
versity Hospital, between July 2007 and January 2010
were screened for eligibility. Aalborg University Hospi-
tal treats some 260–350 patients with colorectal cancer
each year. Each patient was referred from the surgical
outpatient clinic and managed according to the current
Danish guidelines. The inclusion and exclusion criteria
have been described previously12 (ClinicalTrials identifier
NCT00488904).
Briefly, patients in both the n-3 FA and control group
received the ONS as a sip feed (200 ml twice daily, once
in the morning and once in the afternoon) for 7 days
before and 7 days after surgery. The feeds were isocaloric
(1⋅5 kcal/ml) and isonitrogenous (Supportan®; Fresenius
Kabi, Bad Homburg, Germany). Both feeds contained the
same amounts of carbohydrate, protein, total fat and n-6
FA, as well as vitamins and minerals. However, the fatty
acid composition differed between the two feeds: both
contained medium-chain triglycerides, sunflower oil and
safflower oil, but the n-3 FA ONS also contained fish oil.
Thus, patients in the n-3 FA group received 2⋅0 g EPA and
1⋅0 g DHA per day from the ONS, whereas no n-3 FA was
provided to controls.
Outcome measures
Outcomes included perioperative results (pneumonia,
wound infection, urinary tract infection, peritonitis
(including anastomotic leakage) and sepsis) and sur-
vival. Five-year overall survival (defined as being alive
5 years after colorectal cancer surgery) and the risk of
disease recurrence (defined as the cumulative incidence
of local or metastatic colorectal cancer recurrence) at
3 years according to treatment allocation were evaluated.
According to the Danish national guidelines for colorectal
cancer treatment, each patient was followed with CT of
the thorax and abdomen 1 and 3 years after treatment. If
the patient did not have full colonoscopy before surgery, a
new colonoscopy was planned for 3 months after surgery;
otherwise, all patients had colonoscopy 5 years after treat-
ment. Data on patient survival and disease recurrence were
collected from patient records and the Danish National
Patient Registry.
After evaluation of the surgical resection specimen,
the patients were restaged and evaluated at a new mul-
tidisciplinary team conference, after which those with
high-risk stage II and III disease were referred for adjuvant
chemotherapy. Patients with stage IV disease with no
surgically treatable liver metastasis received chemother-
apy with palliative intent only. A subgroup analysis of all
patients receiving adjuvant chemotherapy with curative
intent was also performed, and therefore excluded patients
who had either neoadjuvant radiochemotherapy or post-
operative palliative chemotherapy (patients with stage IV
disease).
Post-trial analysis of survival was approved by the North
Denmark Committee on Health Research Ethics Com-
mittee (N-20140064) and the Danish Data Protection
Agency.
Statistical analysis
The study was designed to detect a 20 per cent difference
in postoperative complication rates between groups (a
reduction from 30 to 10 per cent was hypothesized). The
required sample size was 72 patients in each group (80
per cent power, α = 0⋅05). Baseline characteristics were
compared using Student’s t test or Fisher’s exact test,
as appropriate. The median length of hospital stay was
© 2020 The Authors. www.bjsopen.com BJS Open 2020; 4: 678–684
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Fig. 1 CONSORT diagram for the study
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compared using the Wilcoxon–Mann–Whitney rank
test. The Kaplan–Meier estimator was used to depict the
association between treatment with the n-3 FA ONS and
overall survival. Overall 5-year survival was calculated
from Kaplan–Meier estimates and compared with the log
rank test. To evaluate the effects of a supplement with
n-3 FA along with interaction with adjuvant chemother-
apy, a generalized linear model was constructed using
the pseudo-observation method13. Estimates were pre-
sented as hazard ratios (HRs) with 95 per cent confidence
intervals. The risk of disease recurrence was estimated
using competing risk regression. The Aalen–Johansen
estimator was used to produce the cumulative incidence
plot, and the pseudo-observation method was employed
to determine the relative risk (RR) of disease recur-
rence 3 years after surgery. All analyses were conducted
using STATA® V.15.1 (StataCorp, College Station,
Texas, USA).
Results
Of 610 patients who had colorectal cancer surgery during
the study period, 201 did not meet the inclusion criteria,
31 declined to participate, and 230 could not be included
because they had surgery within 4–5 days of diagnosis and
therefore could not receive the allocated 7-day intervention
before surgery (Fig. 1). The remaining 148 patients were
randomized (in line with the power calculation); however,
23 patients were subsequently excluded owing to patient
refusal, postoperative death, logistical reasons, or because
they did not have a standard colorectal cancer resection.
Accordingly, 65 patients were enrolled in the n-3 FA treat-
ment arm and 60 patients in the control arm.
Baseline characteristics of the patients are shown in
Table 1. Twenty-two patients received adjuvant chemother-
apy, either as monotherapy with 5-FU (5 patients) or as
combined treatment (17) with folinic acid, 5-FU and oxali-
platin (FOLFOX).
© 2020 The Authors. www.bjsopen.com BJS Open 2020; 4: 678–684
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Table 1 Study population
Enriched ONS (n = 65) Control ONS (n = 60) P†
Age (years)* 68⋅3(11⋅3) 70⋅6(10⋅1) 0⋅246‡
Sex ratio (M : F) 27 : 38 30 : 30 0⋅373
Smoking status
Non-smoker 47 (72) 51 (85)
Smoker 17 (26) 8 (13)
Unknown 1 (1⋅5) 1 (2) 0⋅148
Cancer location
Colon 36 (55) 34 (57)
Rectum 29 (45) 26 (43) 1⋅000
UICC stage
I 14 (22) 10 (17)
II 26 (40) 29 (48)
III 18 (28) 19 (32)
IV 7 (11) 2 (3) 0⋅348
Adjuvant therapy 11 (17) 11 (18) 1⋅000
Values in parentheses are percentages unless indicated otherwise; *values are mean(s.d.). ONS, oral nutrition supplement. †Fisher’s exact test, except
‡Student’s t test.
Perioperative outcomes
Data on perioperative outcomes have been reported
elsewhere12. In brief, there was no significant difference in
the number of infectious (35⋅4 per cent in patients treated
with n-3 FA versus 38⋅3 per cent in the control group;
P = 0⋅853) or non-infectious (29⋅2 and 23⋅3 per cent
respectively; P = 0⋅544) complications, 30-day mortality
rate (0 per cent in both groups; P = 1⋅000) or median
length of hospital stay (9 versus 10 days respectively;
P = 0⋅807).
Survival
The 5-year overall survival rate was 69⋅2 (95 per cent
c.i. 56⋅5 to 78⋅9) per cent in patients treated with n-3
FA, compared with 81⋅7 (69⋅3 to 89⋅4) per cent in the
control group (P = 0⋅193). The Kaplan–Meier survival
curves (Fig. 2) indicate that the assumption of proportional
hazards was violated over the recorded time period (which
was also evident from the log–log plot). Therefore, the
pseudo-observation method was used to construct a gener-
alized linear model to evaluate the effect of treatment with
n-3 FA and adjuvant chemotherapy on 5-year survival.
The model was adjusted for age and stage of disease at the
time of diagnosis. The unadjusted HR 5 years after surgery
was 1⋅68 (95 per cent c.i. 0⋅88 to 3⋅21), suggesting no
effect of n-3 FA treatment on survival of surgically treated
patients with colorectal cancer (Table 2). After adjust-
ment for adjuvant chemotherapy, age and stage at time
of diagnosis, supplementation with n-3 FA was associated
Fig. 2 Kaplan–Meier analysis of overall survival according to
treatment allocation
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with a higher overall mortality (HR 1⋅73 (1⋅06 to 2⋅83);
P = 0⋅029).
The interaction between treatment with n-3 FA and
adjuvant chemotherapy was, however, not statistically
significant, suggesting a spurious association. Of patients
treated with adjuvant chemotherapy, the stratified HR for
patients in the n-3 FA group was 2⋅09 (95 per cent c.i. 0⋅92
© 2020 The Authors. www.bjsopen.com BJS Open 2020; 4: 678–684
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Table 2 Hazard ratios for mortality at 5 years after surgery
Univariable estimates Multivariable estimates
Hazard ratio P Hazard ratio P
Age 1⋅05 (1⋅01, 1⋅09) 0⋅011 1⋅07 (1⋅03, 1⋅12) 0⋅001
n-3 fatty acids 1⋅68 (0⋅88, 3⋅21) 0⋅118 1⋅73 (1⋅06, 2⋅83) 0⋅029
Adjuvant chemotherapy 2⋅23 (1⋅23, 4⋅06) 0⋅009 1⋅52 (0⋅87, 2⋅65) 0⋅138
UICC stage
II 1⋅75 (0⋅40, 7⋅66) 0⋅461 3⋅89 (0⋅43, 34⋅71) 0⋅223
III 5⋅19 (1⋅30, 20⋅69) 0⋅020 12⋅57 (1⋅66, 95⋅37) 0⋅014
IV 6⋅67 (1⋅55, 28⋅58) 0⋅011 7⋅87 (1⋅03, 60⋅82) 0⋅047
Values in parentheses are 95 per cent confidence intervals. n-3 FA, omega-3 fatty acids.
Fig. 3 Risk of disease recurrence in patients who had colorec-
tal surgery with curative intent, according to treatment alloca-
tion
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There were 55 patients in the omega-3 fatty acids (n-3 FA) group and 55
in the control group. Relative risk 1⋅66 (95 per cent c.i. 0⋅65 to 4⋅26).
to 4⋅75) compared with 1⋅29 (0⋅51 to 3⋅25) in the control
group (P = 0⋅138).
Disease recurrence
The effect of treatment with n-3 FA on the risk of disease
recurrence, using death as a competing risk, was calculated
for the 110 patients who had an R0 resection (55 in each
group) (Fig. 3). The risk of disease recurrence did not differ
between groups (RR 1⋅66, 95 per cent c.i. 0⋅65 to 4⋅26), and
adjustment for stage and adjuvant chemotherapy did not
alter the estimate.
Discussion
This study aimed to evaluate perioperative treatment with
n-3 FA on the outcomes of patients undergoing colorectal
cancer surgery in a randomized clinical setting. Of note, the
investigation was designed as an RCT, enrolling blinded
participants; the sip feeds were nutritionally similar and
had an identical appearance and taste, apart from content
of marine n-3 FA. Compliance with the allocated interven-
tion (n-3 FA versus control) was acceptable, and the study
population was relatively homogeneous12.
However, the study was powered to show a difference
in postoperative complications and not a difference in sur-
vival in patients receiving chemotherapy and n-3 FA; thus,
the number of patients might have been too low for this
outcome. The low number of patients receiving adjuvant
chemotherapy (11 in each group) also limited the study
power, and any association with reduced survival or other
events should be interpreted with caution. Follow-up on
postoperative dietary habits, other disease states and medi-
cations was not conducted, and this should also be regarded
as a limitation. The intake of long-chain n-3 FA in West-
ern countries is generally low, but is traditionally higher in
Scandinavian countries, and therefore the results may not
be directly comparable for other populations. Finally, other
n-3 FA dosages and different lengths of treatment dura-
tion were not considered. Prolonged treatment might be
needed to ensure an effect on postoperative outcomes.
Some meta-analyses14,15 identified that so-called
immunonutrition, containing arginine, glutamine,
nucleotides and n-3 FA, could reduce postoperative infec-
tions in selected patient groups. However, it is unclear
which of the components is responsible for the clinical
effect. In the present study, daily supplementation with 3 g
EPA plus DHA for 7 days before and 7 days after colorectal
cancer surgery did lead to increased incorporation of these
n-3 FA in the cell membranes, as well as a significant
increase in the production of leukotriene B5 from EPA and
a significant decrease in the production of leukotriene B4,
but had no effect on postoperative complications12,16,17.
It has been suggested18 that supplementation with n-3
FA could increase chemotherapeutic efficacy and thereby
© 2020 The Authors. www.bjsopen.com BJS Open 2020; 4: 678–684
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contribute to increased survival. In a combined analysis
of the Nurses’ Health Study and the Health Professionals
Follow-up Study, it was reported18 that a high intake of
n-3 FA after colorectal cancer diagnosis was associated with
a lower risk of mortality from the disease. Thus, patients
consuming at least 0⋅3 g n-3 FA daily had an adjusted HR
for colorectal cancer-specific mortality of 0⋅59 (95 per cent
c.i. 0⋅35 to 1⋅01). Patients who increased their marine n-3
FA intake by at least 0⋅15 g/day after diagnosis had a HR of
0⋅30 for colorectal cancer death, compared with those who
did not change their intake of marine n-3 FA.
A previous phase II double-blind placebo-controlled
RCT enrolled patients with colorectal cancer and liver
metastases who received 2 g EPA daily or placebo twice
daily from randomization to the day of liver resection10.
The n-3 FA EPA was successfully incorporated into liver
metastases removed at operation, and a trend towards
reduced tumour vascularization in n-3 FA-treated colorec-
tal liver metastases was recorded. The authors report a
non-significant trend towards improved overall survival
from n-3 FA in the first 18 months after surgery, and early
colorectal cancer recurrence was similar in the groups10.
A meta-analysis19 compared RCTs using pharmaconu-
trition with those using standard nutrition in elective adult
surgical patients operated on between 1980 and 2011. No
differences were reported in postoperative mortality, but
there was a significant reduction in infectious complica-
tions and length of hospital stay. Regarding perioperative
administration, there was a reduction in anastomotic
dehiscence. Furthermore, a reduction in non-infectious
complications was detected with postoperative adminis-
tration. Pharmaconutrition given before surgery did not
demonstrate a notable advantage compared with stan-
dard nutrition for any of the assessed clinical outcomes19.
The importance of timing was also shown in another
review20 of published meta-analyses, implying improved
outcome after oncological gastrointestinal surgery, but
before issuing recommendations further studies are war-
ranted. Additionally, two meta-analyses19,21 showed that
preoperative pharmaconutrition did not confer any benefit
over standard formulations. The earlier seen benefits of
pharmaconutrition (reduction in infectious complications)
were reported only with perioperative or postoperative
administration.
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